213 related articles for article (PubMed ID: 25560463)
1. Entecavir allows an unexpectedly high residual replication of HBV mutants resistant to lamivudine.
Geipel A; Seiz PL; Niekamp H; Neumann-Fraune M; Zhang K; Kaiser R; Protzer U; Gerlich WH; Glebe D;
Antivir Ther; 2015; 20(8):779-87. PubMed ID: 25560463
[TBL] [Abstract][Full Text] [Related]
2. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present.
Tenney DJ; Rose RE; Baldick CJ; Levine SM; Pokornowski KA; Walsh AW; Fang J; Yu CF; Zhang S; Mazzucco CE; Eggers B; Hsu M; Plym MJ; Poundstone P; Yang J; Colonno RJ
Antimicrob Agents Chemother; 2007 Mar; 51(3):902-11. PubMed ID: 17178796
[TBL] [Abstract][Full Text] [Related]
3. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
4. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.
Tenney DJ; Levine SM; Rose RE; Walsh AW; Weinheimer SP; Discotto L; Plym M; Pokornowski K; Yu CF; Angus P; Ayres A; Bartholomeusz A; Sievert W; Thompson G; Warner N; Locarnini S; Colonno RJ
Antimicrob Agents Chemother; 2004 Sep; 48(9):3498-507. PubMed ID: 15328117
[TBL] [Abstract][Full Text] [Related]
5. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
Amini-Bavil-Olyaee S; Herbers U; Luedde T; Trautwein C; Tacke F
J Viral Hepat; 2011 Nov; 18(11):804-14. PubMed ID: 20887378
[TBL] [Abstract][Full Text] [Related]
6. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient.
Villet S; Ollivet A; Pichoud C; Barraud L; Villeneuve JP; Trépo C; Zoulim F
J Hepatol; 2007 Mar; 46(3):531-8. PubMed ID: 17239478
[TBL] [Abstract][Full Text] [Related]
7. Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection.
Karatayli E; Karatayli SC; Cinar K; Gokahmetoglu S; Güven K; Idilman R; Yurdaydin C; Bozdayi AM
J Clin Virol; 2012 Feb; 53(2):130-4. PubMed ID: 22078148
[TBL] [Abstract][Full Text] [Related]
8. Impacts of HBV rtH55R polymerase substitution on viral replication and rtM204I/V resistance to nucleoside/nucleotide antiviral drugs.
Xiang KH; Zhao CY; Wang S; Li Y; Su MZ; Wang QY; Xu XZ; Deng J; Zhuang H; Li T
Antivir Ther; 2018; 23(1):33-42. PubMed ID: 28440785
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response.
Baldick CJ; Eggers BJ; Fang J; Levine SM; Pokornowski KA; Rose RE; Yu CF; Tenney DJ; Colonno RJ
J Hepatol; 2008 Jun; 48(6):895-902. PubMed ID: 18362040
[TBL] [Abstract][Full Text] [Related]
10. Analysis of HBV genotype, drug resistant mutations, and pre-core/basal core promoter mutations in Korean patients with acute hepatitis B.
Lee JH; Hong SP; Jang ES; Park SJ; Hwang SG; Kang SK; Jeong SH
J Med Virol; 2015 Jun; 87(6):993-8. PubMed ID: 25712861
[TBL] [Abstract][Full Text] [Related]
11. Generation of a human hepatoma cell line supporting efficient replication of a lamivudine resistant hepatitis B virus.
Zhang Y; Zhang Y; Kang Y; Wang J; Liu H; Zhu H; Qin Y; Mao R; Lin X; Lu M; Zhang J
J Virol Methods; 2014 Jun; 201():51-6. PubMed ID: 24583110
[TBL] [Abstract][Full Text] [Related]
12. Do different lamivudine-resistant hepatitis B genotypes carry the same risk of entecavir resistance?
Lee GH; Aung MO; Dan YY; Lee YM; Mak B; Low HC; Lim K; Thwin MA; Tan PS; Lim SG
J Med Virol; 2013 Jan; 85(1):26-33. PubMed ID: 23023992
[TBL] [Abstract][Full Text] [Related]
13. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.
Reijnders JG; Deterding K; Petersen J; Zoulim F; Santantonio T; Buti M; van Bömmel F; Hansen BE; Wedemeyer H; Janssen HL;
J Hepatol; 2010 Apr; 52(4):493-500. PubMed ID: 20185191
[TBL] [Abstract][Full Text] [Related]
14. Redetection of HBV lamivudine-resistant mutations in a patient under entecavir therapy, who had been treated sequentially with nucleos(t)ide analogues.
Rodriguez-Frias F; Jardi R; Schaper M; Gimferrer M; Elefsiniotis I; Tabernero D; Esteban R; Buti M
J Med Virol; 2007 Nov; 79(11):1671-3. PubMed ID: 17854030
[TBL] [Abstract][Full Text] [Related]
15. Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients.
Yang JX; Liu BM; Li XG; Yan CH; Xu J; Sun XW; Wang YH; Jiao XJ; Yan L; Dong JP; Hou CS; Abuduheilili X; Li T; Zhuang H
Antivir Ther; 2010; 15(8):1171-8. PubMed ID: 21149924
[TBL] [Abstract][Full Text] [Related]
16. Dynamics of hepatitis B virus resistance substitutions correlates with virological response in lamivudine-refractory patients with entecavir rescue monotherapy.
Zhang Y; He S; Li QL; Guo JJ
Virus Res; 2013 Nov; 177(2):156-62. PubMed ID: 23968804
[TBL] [Abstract][Full Text] [Related]
17. A novel method for nucleos(t)ide analogues susceptibility assay of hepatitis B virus by viral polymerase transcomplementation.
Luo YY; Tao Y; Cai XF; Zhang WL; Long QX; Guo H; Huang AL; Hu JL
Antiviral Res; 2016 Feb; 126():99-107. PubMed ID: 26738784
[TBL] [Abstract][Full Text] [Related]
18. Impact of lamivudine-resistance mutations on entecavir treatment outcome in hepatitis B.
Koffi J; Egounlety R; Pradat P; Lebosse F; Si-Ahmed SN; Lussier V; Chevallier P; Bailly F; Zoulim F
Eur J Gastroenterol Hepatol; 2014 Feb; 26(2):146-54. PubMed ID: 24025974
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy.
Pessôa MG; Gazzard B; Huang AK; Brandão-Mello CE; Cassetti I; Mendes-Corrêa MC; Soriano V; Phiri P; Hall A; Brett-Smith H
AIDS; 2008 Sep; 22(14):1779-87. PubMed ID: 18753861
[TBL] [Abstract][Full Text] [Related]
20. Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants.
Chen CH; Wang JH; Lu SN; Hu TH; Hung CH; Chang MH; Changchien CS; Lee CM
Antivir Ther; 2012; 17(4):701-9. PubMed ID: 22358132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
